Establishment of two vaccine-associated feline sarcoma cell lines and determination of in vitro chemosensitivity to doxorubicin and mitoxantrone.
OBJECTIVE
To establish 2 vaccine-associated feline sarcoma (VAFS) cell lines and to determine their in vitro sensitivity to the chemotherapeutic agents doxorubicin and mitoxantrone.


METHODS
Tumor specimens collected from 2 cats undergoing surgery for removal of vaccine-associated sarcomas.


METHODS
Tumor specimens were minced and treated with trypsin under aseptic conditions to obtain single-cell suspensions, which were then cultured in vitro in medium supplemented with 5% heat-inactivated fetal bovine serum. Growth rates and sensitivity after 24 hours of exposure to various concentrations (0.1 to 100 microg/ml) of doxorubicin and mitoxantrone were assessed for each cell line. Survival of cells was estimated 3 days after exposure to the 2 agents, and the concentration of each drug that resulted in a 50% reduction in the number of viable cells (IC50) was calculated.


RESULTS
Two tumor-derived cell lines (FSA and FSB) were successfully established and determined to be sensitive to doxorubicin and mitoxantrone. Under the conditions tested, the IC50 of doxorubicin were 0.6 and 1.5 microg/ml for cell lines FSB and FSA, respectively. The IC50 of mitoxantrone was 0.4 microg/ml for both cell lines.


CONCLUSIONS
The establishment of VAFS cell lines provides a tool for the in vitro screening of antitumor drugs. Doxorubicin and mitoxantrone were effective in decreasing the number of viable cells in the 2 cell lines tested. Both of these anthracycline antibiotics have been used to treat various neoplasias in cats, and their efficacy for adjuvant treatment of vaccine-associated sarcomas should be further evaluated.
Williams
L E
LE
Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul 55108, USA.
Banerji
N
N
Klausner
J S
JS
Kapur
V
V
Kanjilal
S
S
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002371:Cat Diseases / Q000188:drug therapy / Q000473:pathology*; D002415:Cats; D018929:Cell Culture Techniques; D004317:Doxorubicin / Q000494:pharmacology*; D005260:Female; D020128:Inhibitory Concentration 50; D008297:Male; D008942:Mitoxantrone / Q000494:pharmacology*; D012509:Sarcoma / Q000188:drug therapy* / Q000473:pathology / Q000662:veterinary*; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014611:Vaccination / Q000009:adverse effects / Q000662:veterinary*
D000970:Antineoplastic Agents; D004317:Doxorubicin; D008942:Mitoxantrone